Sustainability
A global pioneer in the development of new drugs
SHE Management & Net Zero
SHE (Safety, Health and Environment) Management
SK Biopharmaceuticals has established a “SHE Policy" as the foundation for its environmental management in order to address the demands of both
internal and external stakeholders (including employees, partner companies, external evaluators, etc.) and promote the sustainability of the
company.
We are committed to minimizing its environmental impact in its business activities by establishing a company-wide environmental management strategy, objectives, and performance criteria. The appropriateness of these measures is reviewed annually through management reporting and presentation to the ESG/Strategic Committee under the Board of Directors. In addition, SK Biopharmaceuticals regularly reviews and approves environmental/safety management performance through the establishment, inspection, and evaluation of KPIs by establishing the ESG/Strategic Committees makes major decisions and processional deliberation in Safety, Health and Environment (SHE).
It also operates environmental impact assessment procedures related to air and water pollutant emissions, waste, greenhouse gases, energy, and water for all board agendas. The CEO is responsible for environmental management, and the internal regulations, Environmental Manual, stipulate the authority to ensure the appropriateness of environmental policies and environmental objectives. The CEO's responsibility and authority is to approve management reviews that include achieving environmental goals, compliance with laws and regulations, and continuous improvement tasks.
To strengthen environmental management at all stages of research, the ESG/Strategic Committee, a meeting consisted of one executive director and one non-executive director, is held once a year to discuss risks and countermeasures, and important decisions are reported to the Board and management.
Under the leadership of Chief Executive Officer (CEO) and Chief Technology Officer (CTO), who plays a role in the Health and Safety Management Officer, the Headquarters established and implements the Environmental Safety and Health Plan.
We are committed to minimizing its environmental impact in its business activities by establishing a company-wide environmental management strategy, objectives, and performance criteria. The appropriateness of these measures is reviewed annually through management reporting and presentation to the ESG/Strategic Committee under the Board of Directors. In addition, SK Biopharmaceuticals regularly reviews and approves environmental/safety management performance through the establishment, inspection, and evaluation of KPIs by establishing the ESG/Strategic Committees makes major decisions and processional deliberation in Safety, Health and Environment (SHE).
It also operates environmental impact assessment procedures related to air and water pollutant emissions, waste, greenhouse gases, energy, and water for all board agendas. The CEO is responsible for environmental management, and the internal regulations, Environmental Manual, stipulate the authority to ensure the appropriateness of environmental policies and environmental objectives. The CEO's responsibility and authority is to approve management reviews that include achieving environmental goals, compliance with laws and regulations, and continuous improvement tasks.
To strengthen environmental management at all stages of research, the ESG/Strategic Committee, a meeting consisted of one executive director and one non-executive director, is held once a year to discuss risks and countermeasures, and important decisions are reported to the Board and management.
Under the leadership of Chief Executive Officer (CEO) and Chief Technology Officer (CTO), who plays a role in the Health and Safety Management Officer, the Headquarters established and implements the Environmental Safety and Health Plan.
Targets
Short-Term Reduction Goal(~2025)
| Core Objective | Performance in 2022 | Plans for 2023 |
|---|---|---|
| · A 1% annual reduction in hazardous substance emissions by 2025 | · In 2022, the generated waste amount was approximately 41.8 tons, achieving a reduction of around 10% compared to the target of 46.3 tons | · Setting a target of 41.4 tons for waste generation in 2023, aiming for a reduction of approximately 1% compared to 2022 |
Long-Term Reduction Goal(~2035)
: Reduction rate of hazardous substance emissions intensity compared to the previous year| Classification | Unit | Reduction Target (~2026) |
Reduction Target (~2028) |
Reduction Target (~2030) |
Reduction Target (~2035) |
|---|---|---|---|---|---|
| Air Pollutants | % | -44 | -56 | -66 | -80 |
| Water Pollutants | % | -44 | -53 | -62 | -74 |
| Waste Disposal Amount | % | -41 | -50 | -58 | -71 |
※ Intensity (kg/one billion won) =Hazardous substance emissions (kg) / Revenue from products and other sources(one billion won)
Roadmap for Advancing Safety and Health Management System
| Classification | Phase1 (2023) | Phase2 (2024) | Phase3 (2025) |
|---|---|---|---|
| Goals for Advancing Safety Management System |
|
|
|
| Goals for Advancing Health Management System |
|
|
|
Performances
Greenhouse Gas Emission Reduction Goals and Performance (Third-party External Verification Data Basis)
| Year | Greenhouse Gas Emission Forecast(tCO2eq) [BAU : Business As Usual] |
RE100(Green Premium Tariff) Reduction Amount (tCO2eq) |
Offset Emission Ratio Compared to BAU (%) |
|
|---|---|---|---|---|
| Scope 1 (Direct Emissions, tCO2eq) |
Scope 2 (Indirect Emissions, tCO2eq) |
|||
| 2021 | 394 | 892 | 447 | 0 |
| 2022 | 425 | 873 | 436 | 0 |
1) Excluded from Emission Trading Scheme (ETS): No offset emissions
Health and Safety Management Activities for Employee
SK Biopharmaceuticals recognizes that employee safety and health issues can be a significant concern that may lead to personal harm and a decline in corporate reputation. For that reason, we conduct risk assessments for all facilities, operations, and chemicals within our workplace at least once a year.We identify all potential hazards through on-site inspections, evaluate their risks based on company regulations, and then develop and implement improvement measures to minimize these risks.
Furthermore, we operate a "Safety and Health Suggestion System" where our members can report potential hazards they have identified. These reports are collected and taken into consideration during evaluations. This approach effectively helps prevent human errors and minor incidents.
Additionally, we conduct emergency response training for our members at least once a year, continuing our efforts in accident prevention. 1) Risk Assessment Performance (As of 2022, with the 2023 assessment scheduled for the fourth quarter)
| Total (ea) | Development of Risk Mitigation Measures (ea, %) |
Major Improvement Results | Major Recurrence Prevention Measures | ||
|---|---|---|---|---|---|
| Goal | Completed | Rate of Improvement |
|||
| 49 | 49 | 49 | 100 |
|
|
| No. | Training Scenario | Major Training Topic |
|---|---|---|
| 1 | De-freezer Refrigerator Temperature Increase/Overheating | Replacing Circuit Breaker, Relocating Storage Chemicals |
| 2 | Wastewater Storage Tank Leak | Locating the Leak Area, Recovery Operation for Leaked Wastewater |
| 3 | Equipment Failure Due to Condensate Storage Tank Leak | Condensate Recovery Operation, Recovery of Malfunctioning Equipment |
Safety·Health Management System
SK Biopharmaceuticals recognizes that workplace safety and health issues are critical concerns that can directly result in human harm.Under the leadership of the Safety and Health team, we hold industry safety and health committee meetings at least once every quarter to actively solicit and manage members' opinions on safety and health matters. Furthermore, we have established an employee and partner company occupational management system to achieve our three-year long-term goals for advancing safety and health management excellence, in alignment with enhancing safety and health management practices.
Operation of Safety/Health/Environmental Management System
SK Biopharmaceuticals holds safety and health management systems as well as environmental management systems for its domestic and international facilities, including research facilities at its headquarters in Korea. In accordance with international standards, the company conducts regular safety, health, and environmental compliance audits to assess the adherence to regulatory requirements and compliance. These efforts contribute to the continuous improvement of the SHE (Safety, Health, and Environment) management systems.Compliance Audit Status for SHE Management
SK Biopharmaceutics obtained the Safety and Health Management System (ISO 45001: 2018) and the Environmental Management System (ISO 14001: 2015) for the Headquarters with research facilities. According to the international standard system, we continue to make efforts to improve the SHE management system by conducting periodic safety, health, and environmental regulations and compliance audits.| Classification | Audit Cycle | Audit Leading Department |
|---|---|---|
| Initial Stage 1+2 | Initial One-time | External Audit Agency (LRQA, KFQ) |
| Internal Audit | Once a year | SHE Team |
| Surveillance | Once a year | External Audit Agency (LRQA, KFQ) |
| Re-Certification | Once every 3 years | External Audit Agency (LRQA, KFQ) |
International Certification
ISO 14001 Certification (As of June 2023)| Certification Type | Scope | Acquisition date | Examiner |
|---|---|---|---|
| ISO 45001 (Safety & Health Management System) |
Headquarters : Development of new medicine (Completed 100% : 1 out of 1 site) |
May 11, 2023 | LRQA |
| ISO 14001 (Environmental Management System) |
May 23, 2022 | Korean Foundation for Quality (KFQ) |
Certificates
-
ISO 14001 (Environmental Management System)
-
ISO 45001(Safety & Health Management System)
NET ZERO
SK Biopharmaceuticals recognizes climate change adaptation as an essential element of its management strategy and has declared the goal of achieving net zero greenhouse gas emissions by 2040, aiming to reach a net emissions level of zero by 2040.
This declaration is based on the '2040 Net Zero Roadmap’, which was formulated adopting the RCP-2.6 scenario used in the IPCC Fifth Assessment Report. The Roadmap has been supplemented with socio-economic elements using the SSP1-2.6 (Shared Socioeconomic Pathways) scenario, as featured in the IPCC Sixth Assessment Report published in May 2022.
Through this, SK Biopharmaceuticals commits to actively participating in achieving low-emission scenarios, limiting global warming to 1.5 degrees Celsius, and planning and implementing practical mitigation measures.
Achievement Plan for Net Zero
Short-Term and Long-Term Key Initiatives
Indirect Greenhouse Gas Reduction Status (Recent 3-year)
| Company Name | Initiative Project Title | Reduction Amount | Performance Period |
|---|---|---|---|
| SK Biopharmaceuticals Co., Ltd. (HQs) |
RE100 (Green Premium Tariff) | 447 | 07.2021 ~ 12.2021 |
| 436 | 03.2022 ~ 12.2022 | ||
| 579 | 01.2023 ~ 12.2023 |